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Abstract
Background: Phosphatidylethanolamine (PE) is a phospholipid which is biosynthesized into long
chain N-acylethanolamines (NAEs) including oleoylethanolamide (OEA), a known inhibitor of food
intake. The aim of this study was to investigate whether PE-containing lipids can also inhibit intake.
This was a 4 treatment intervention where 18 male participants were given a high-fat test breakfast
(2.5MJ, 53 en% fat) containing (i) high-phospholipid, high-PE lipid (ii) high-phospholipid, medium-PE
lipid (iii) no-phospholipid, no-PE control lipid or (iv) water control, in a randomised cross-over.
Visual analogue scales (VAS) were used to assess post-ingestive hunger and satiety, and energy
intake (EI) was measured at an ad libitum lunch meal after 3.5hours.
Results: When compared with the water control, the 3 lipid treatments resulted in lower levels
of hunger and thoughts of food, greater fullness and satisfaction (all, treatment*time interaction,
P<0.001), and a lower EI (P<0.05). However, there was no difference in any of the VAS measures
when the 2 PE lipid treatments were compared with no-PE control lipid, nor when medium-PE was
compared with high-PE. Unexpectedly participants ate significantly more energy at the lunch meal
when the 2 PE lipid treatments (medium-PE:5406 kJ, 334 sem; high-PE:5288 kJ, 244 sem) were
compared with the no-PE control lipid (5072 kJ, 262 sem, P<0.05), although there was no dose
effect between the medium- and high-PE treatments.
Conclusion: Despite the close relationship of PE with OEA, there was no evidence from this acute
study that dietary phospholipids containing PE can favourably modify eating behaviour.
Introduction
The inability to control energy intake (EI), compounded
by low levels of physical activity, appears key to the devel-
opment of obesity. Regulation of appetite is central to the
control of weight gain, and identifying foods which can
modulate hunger and satiety and hence decrease intake is
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an area of considerable interest. There is a body of data
which suggests that dietary lipids may be the least satiat-
ing of the 3 food macronutrients [1-4], but that the phys-
icochemical properties such as fatty acid saturation [5-7],
fatty acid chain length [8], and fat emulsification and
intestinal delivery rates [9-12] may all affect the degree to
which lipids can control hunger. Given the sensory appeal
of dietary fat and the fact that it comprises such a high per-
centage of the Western diet (35–45% energy), the identi-
fication of highly satiating lipid products would be
attractive.
Phospholipids (PL) are crucial lipid components of bio-
logical membranes and, whilst present in the diet in much
smaller gram amounts than triglycerides, are found typi-
cally in items including eggs, dairy, liver and oils such as
soybean. Whilst phosphatidylcholine (PC, also known as
lecithin) is the most abundant PL in animal tissues [13],
phosphatidylethanolamine (PE) is also found in biologi-
cal membranes and hence is also consumed within our
diet. PLs are commonly used as emulsifiers within the
food industry. Of particular interest in the area of appetite
regulation is PE which is known to be metabolized endog-
enously into a range of ethanolamides of long chain fatty
acids, collectively termed the N-acylethanolamines
(NAEs), and which include N-arachidonoylethanolamine
(anandamide) and its analogue oleoylethanolamide
(OEA) [14]. OEA is a lipid which has become prominent
as an established inhibitor of food intake in animal mod-
els and which appears to regulate feeding through activa-
tion of the nuclear receptor peroxisome-proliferator-
activated receptor-α (PPAR-α) [15,16]. OEA decreases
food intake by as much as 40–70% when introduced both
by intra-peritoneal injection [15,17] and orally [18] into
long-term fasted animals. Hence OEA has become a pos-
sible therapeutic target for modification of food intake
and subsequent weight loss in humans. Effects of OEA are
rapid with significant changes in food intake observed 60
minutes post-dose [18] and maintained over a period of
12 hours.
In light of the novel anorectic effects of OEA, this trial was
designed to investigate whether dietary PE may also
enhance satiety. To determine whether PE-containing PLs
affect appetite regulation, a high-fat test-breakfast con-
taining zero, medium or high doses of PE were given to a
group of healthy male participants. Hunger ratings were
measured through the morning and EI covertly measured
at a buffet style meal presented for lunch.
Results
Subjects
Eighteen lean, healthy men completed this 4 treatment
trial. Baseline characteristics are provided in Table 1.
There was no significant difference in body weight at base-
line between the 4 treatments nor was there a change in
body weight, BMI or waist circumference throughout the
trial (data not shown). There was no significant difference
in mean reported EI (high-PE = 9664, kJ 717 sem;
medium-PE = 8782 kJ, 511 sem; no-PE control lipid =
9685 kJ, 485 sem; water control = 8877 kJ, 784 sem; P >
0.05) or mean physical activity level (high-PE = 3.8, 0.7
sem; medium-PE = 3.2, 0.5 sem; no-PE control lipid = 4.0,
0.8 sem; water control = 5.0, 1.2 sem; hours spent on
mild-moderate activity, P > 0.05) on the day prior to each
treatment visit.
Visual analogue scales (VAS)
Palatability of the test-breakfast
The lipid containing test-breakfasts (high-PE, medium-PE
and no-PE control lipid) were designed to be as similar in
appearance and taste as possible, with no significant dif-
ference in total energy, fat, carbohydrate (CHO) or pro-
tein content, as shown in Table 2. Mean ratings for
pleasantness, visual appeal, smell, taste, after-taste and
palatability of the 3 lipid containing test-breakfasts and
the water control were self-reported through completion
of VAS immediately after the breakfast on each occasion,
as shown in Figure 1. There was a significant effect of treat-
ment on measures of pleasantness, visual appeal, smell,
taste, aftertaste and palatability when all 4 treatments
were included in the analysis (P < 0.001), a consequence
of inclusion of the water control treatment in the ANOVA.
When post-hoc analyses were carried out, there was no sig-
nificant difference between the 3 lipid-containing treat-
ments in pleasantness, visual appeal, smell, taste, after-
taste and palatability (P > 0.05) demonstrating that per-
ceived differences in the test-breakfast were not responsi-
Table 1: Baseline characteristics of the 18 males who completed 
the intervention.
Mean sd
n1 8
Age (y) 25 7.5
Body weight (kg) 70.7 8.3
BMI (kg/m2) 22.1 2.2
Waist circumference (cm) 77.0 5.2
Total cholesterol (mmol/L) 4.0 0.8
LDL-C (mmol/L) 2.1 0.7
HDL-C (mmol/L) 1.5 0.2
Triglycerides (mmol/L) 0.8 0.4
TC:HDL-C ratio 2.7 0.5
Glucose (mmol/L) 4.4 0.3
SBP (mm Hg) 114 10
DBP (mm Hg) 68 6
All measurements made at screen visit.
BMI, body mass index; LDL-cholesterol, low density lipoprotein 
cholesterol; HDL-cholesterol, high density lipoprotein cholesterol; 
TC:HDL-C ratio, Total cholesterol: high density lipoprotein-
cholesterol ratio; SBP, systolic blood pressure; DBP, diastolic blood 
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Mean (sem) visual analogue scale (VAS) showing scores for pleasantness, visual appeal, smell, taste, after-taste and palatability of  the 4 test-breakfasts Figure 1
Mean (sem) visual analogue scale (VAS) showing scores for pleasantness, visual appeal, smell, taste, after-taste 
and palatability of the 4 test-breakfasts.
Table 2: Composition of the four test-breakfasts
High-PE lipid Medium-PE lipid No-PE control lipid Water control
Energy (MJ) 2.48 2.48 2.46 0
Fat (g) 35.6 35.6 35.3 0
Fat (% en) 53.1 53.2 53.0 0
CHO (g) 41.9 41.9 41.6 0
CHO (% en) 27.0 27.1 27.1 0
Protein (g) 25.8 25.8 25.8 0
Protein(% en) 17.7 17.7 17.9 0
PL (g) 2.42 1.96 0.10 0
PE (g) 0.68 0.57 0.04 0
PE, phosphatidylethanolamine; PL, phospholipid; CHO, carbohydrate
Energy and macronutrient composition of the four test-breakfasts was calculated using the dietary program FoodWorks™ (Professional Edition, 
Version 2.10.136, 1998–2000; Xyris Software)Lipids in Health and Disease 2008, 7:41 http://www.lipidworld.com/content/7/1/41
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ble for any differences in EI that may later occur at the ad
libitum  lunch. There was also no significant difference
when the 2 PE treatments were compared with the no-PE
control lipid (P > 0.05).
Hunger and satiety
The mean VAS ratings for hunger, fullness, satisfaction
and thoughts of food measured throughout each study
day on the 4 treatment arms are shown in Figure 2. There
was no significant difference in hunger, fullness, satisfac-
tion or thoughts of food between any of the treatments at
baseline when subjects were fasted. Immediately follow-
ing the test breakfast hunger rapidly decreased and full-
ness increased in all 3 lipid treatments in response to the
energy bolus. By 210 minutes (prior to the ad lib lunch)
both hunger and fullness had gradually returned to close
to fasting levels. There was no change in VAS measures for
the water control. As expected, when analyzed over the 3.5
h post-test-breakfast period, there was a significant effect
of the 4 treatments on hunger, fullness, satisfaction and
thoughts of food (treatment, P < 0.001), again a conse-
quence of inclusion of the no-energy water control in the
analyses. There was also a significant difference between
the treatments over time (treatment*time, interaction, P <
0.001). When post-hoc analyses were carried out and the
two PE treatments combined and compared with water
control, there was a significant difference for all 4 VAS
measures between treatments (treatment, P < 0.05), but
there was no significant difference in hunger, fullness, sat-
isfaction or thoughts of food when compared with the no-
PE control lipid (P > 0.05). When the high-PE was com-
pared directly with the medium-PE treatment, there was
also no significant difference in hunger, fullness, satisfac-
tion or thoughts of food as measured by VAS (P > 0.01).
Ad libitum lunch
The mean energy and macronutrient intakes and the total
weight of food consumed at the ad libitum lunch are pre-
sented in Table 3. As expected, there was a significant dif-
ference in EI at lunch between the 4 treatments (P < 0.05),
driven primarily by the high intake following the 0 kJ
water control treatment. Energy intake was 503 kJ, 385 kJ
Mean (sem) visual analogue scale (VAS) showing scores for hunger, fullness, satisfaction and thoughts of food throughout the  day Figure 2
Mean (sem) visual analogue scale (VAS) showing scores for hunger, fullness, satisfaction and thoughts of food 
throughout the day. Lunch was given immediately after VAS assessment at 210 minutes. High-PE (n), Medium-PE (s), No-PE 
control lipid (t), Water control ().Lipids in Health and Disease 2008, 7:41 http://www.lipidworld.com/content/7/1/41
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and 719 kJ lower than for the water control when the
high-PE, medium-PE or no-PE (neutral lipid control)
lipid treatments respectively were given. It was notable
that complete or even near complete compensation for
the 2.5 MJ breakfast was not achieved on any lipid treat-
ment. Greatest compensation occurred on the no-PE neu-
tral lipid control and was only 29% of the energy provided
in the breakfast. Post-hoc  analyses revealed that signifi-
cantly greater energy was consumed at lunch when the
two PE lipid treatments (5347 kJ, 204 sem) were com-
bined and compared with the no-PE control lipid (5072
kJ, 262 sem, P < 0.05), however there was no significant
difference between the high-PE (5288 kJ, 244 sem) and
medium-PE (5406 kJ, 334 sem) treatments. When com-
position of the lunch was examined across the 4 treat-
ments there were significant differences between the
intake of all 3 macronutrients (fat, CHO, protein; all, P <
0.05, Figure 3). This was again driven primarily by the 0 kJ
water control where macronutrient intake mirrored EI and
was high at the lunch meal. When the two PE treatments
were compared with the no-PE control lipid, there was no
significant difference in the intake of either fat or protein
but there was a significantly greater intake of CHO in the
two PE arms (P < 0.05) which lead to the observation of
higher EI on these treatments. When the high-PE was
compared with the medium-PE treatment, there was no
difference in intake of CHO or protein but a difference
was present in grams of fat consumed (P < 0.05).
Discussion
Despite its relationship with the known anorectic lipid
OEA, there was no evidence from this intervention that
the phospholipid PE altered perceptions of hunger and
fullness or decreased food intake. This was a short-term
assessment of appetite regulation in a group of lean men
who arguably are likely to have good physiological regu-
lation of appetite control. There are several issues that
should be considered, including the appropriateness of
the study design to detect relatively small changes in appe-
tite control. There are a wide range of published methods
by which appetite has been assessed and our current trial
methodology was based on well known lipid emulsion
trials [9-11]. The buffet lunch was given 3.5 h after the HF
test-breakfast and the methodology was shown to be sen-
sitive to changes in energy load for both VAS and ad lib
intake. High, medium and no PE treatments decreased EI
by 9, 7 and 12% respectively compared to the water treat-
ment, equivalent to a decrease of between 385–719 kJ at
the buffet lunch. Secondly, to assess whether the buffet
style lunch may have masked physiological changes in
appetite by encouraging over-consumption at the ad lib
meal it was possible to compare the predicted daily intake
Mean (sem) energy and macronutrient intake at the ad libitum lunch Figure 3
Mean (sem) energy and macronutrient intake at the ad libitum lunch.Lipids in Health and Disease 2008, 7:41 http://www.lipidworld.com/content/7/1/41
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of the participants (~10.2 MJ/d, based upon 1.4 × resting
expenditure) with mean intake at the lunch meal and con-
clude that overeating did not occur to any significant
degree. Previous trials have described over-consumption
when ~7 MJ was eaten at a single meal in participants with
predicted energy requirements comparable to that of the
subjects in our current trial [19]. Thirdly, the participants
were blinded to the 3 lipid treatments and VAS scores con-
firmed that there were no detectable differences in pleas-
antness, visual appeal, smell, taste, after-taste or
palatability which may have affected hunger scores or
food intake.
Dietary fat is believed to be the least satiating of the 3 food
macronutrients [1-3,20], and high-fat diets may give rise
to over-consumption due to the fact that fat may be less
effective than CHO and protein in signalling satiety
[2,21,22]. Preliminary evidence exists which indicates
that differential satiating characteristics of lipids may be
driven by physicochemical properties such as fatty acid
saturation [5,7], fatty acid chain length [8] and fat emulsi-
fication [9-12]. For example some studies have demon-
strated that PUFA may exert relatively stronger control
over appetite than MUFA or SFA[5,7], although this is not
a universal finding [23,24]. This has been purported to be
the consequence of an oxidative gradient whereby PUFA
and MUFA may be oxidized more rapidly than SFA [25-
27]. There is also evidence that fatty acid chain length may
affect satiety, with data from early animal [28] and human
[8] studies where EI was decreased on a diet enriched with
high medium chain (MCT) versus long chain triglyceride
(LCT). In addition Burns and colleagues have demon-
strated that lipid/water emulsions may significantly
decrease energy and macronutrient intake at a single meal
[10] and over 24 hours [9] when compared with isoener-
getic non-emulsified lipid. These studies have recently
been supported by longer term data showing improved
weight maintenance in overweight participants adminis-
tered a lipid emulsion [29].
Fats and oils are neutral compounds. Replacement of a
fatty acid within a triglyceride by a phosphate group
results in a PL with 2 non-polar hydrophobic tails and a
charged hydrophilic head. Two fatty acids are esterified to
glycerol, which is linked through phosphate to a polar
head group which in turn may comprise several different
compounds; for example choline, serine or ethanolamine
[30]. A variety of biochemically important molecules can
be obtained by forming a second ester linkage to the phos-
phate group and of these phosphate diesters, often called
phosphatides, the two most biologically important are PE
and PC. PLs are found in the diet in items such as eggs,
peanuts, liver, sunflower and soybean oil and the average
intake of PL is ~5% (w/w) of total fat consumed. PE is
known to play a role in the production of endogenous
OEA which is an analogue of the endogenous cannabi-
noid anandimide [17] and which has been shown to
inhibit food intake in starved rats [31]. PE is metabolized
endogenously into a range of NAEs which are ethanola-
mides of long chain fatty acids, and which include N-ara-
chidonoylethanolamine (anandamide) and its analogue
OEA [14].
Rodriguez de Fonseca and colleagues demonstrated that
food deprivation markedly decreased OEA biosynthesis in
the small intestine[17], and that intraperitoneal adminis-
tration of OEA caused a decrease in food intake where it
may act locally on sensory fibres in the intestine. Fu and
colleagues then demonstrated that OEA binds with high
affinity to PPAR-α, a nuclear receptor that regulates sev-
eral aspects of lipid metabolism [32], and found that
administration of OEA induces satiety and decreases body
weight gain in wild-type mice, but not in mice deficient in
PPAR-α[15]. It was hypothesized that OEA would not be
orally active because of putative excessive catabolism in
the gastrointestinal tract, where a high level of the enzyme
fatty acid amide hydrolase is found [33,34]. However, it
has since been shown that oral OEA inhibited food intake
dose dependently at 90 minutes after food presentation to
starved rats [18]. Food intake was decreased by 15.5% by
administration of 10 mg/kg OEA. Certainly OEA has
proven itself to be an interesting candidate as a satiating
factor and other PLs such as PE may be active in a similar
way.
Table 3: Energy and macronutrient intake at ad libitum lunch
High-PE lipid Medium-PE lipid No-PE control lipid Water control
Energy (kJ) 5288 (244) 5406 (334) 5072 (262) 5792 (233)
Fat (g) 31.2 (2) 35.2 (3) 31.0 (2) 36.3 (2)
Fat (% en) 22 (0.7) 24 (1.2) 22 (1.0) 23 (0.9)
CHO (g) 183.7 (8.4) 184.1 (11.1) 173.8 (9.7) 197.7 (9.5)
CHO (% en) 56 (1) 55 (1) 58 (1) 55 (1)
Protein (g) 61.0 (5) 58.2 (5) 57.8 (5) 65.3 (4)
Protein (% en) 19.5 (1) 18.3 (1) 19.8 (1) 19.3 (1)
Weight of food (g) 1273 (54) 1231 (69) 1245 (61) 1343 (55)
Mean (sem); PE, phosphatidylethanolamine; CHO, carbohydrate; % en, % of energyLipids in Health and Disease 2008, 7:41 http://www.lipidworld.com/content/7/1/41
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The dose of PE used in our study varied increased across
treatments. The neutral lipid control contained little or no
PL or PE, medium-PE treatment contained 1.96 g PL and
565.3 mg PE (equivalent to 8.08 mg/kg in a 70 kg individ-
ual) and high-PE treatment contained 2.42 g PL and 682.4
mg PE (equivalent to 9.75 mg/kg in a 70 kg individual).
These doses were comparable with that of Rodriguez de
Fonseca and colleagues who administered 5–20 mg/kg
intraperitoneally [17] and Nielsen and colleagues who
administered 10 mg/kg oral OEA [18]. Interestingly, sen-
sory tests carried out using human participants in our lab-
oratory prior to our current study showed that the
relatively unpleasant taste of PL would prevent very high
dose lipid administration. In our current study 2.4 g was
added to a large 2.5 MJ breakfast in order to mask the dis-
tinctive flavour.
Conclusion
In conclusion, there was no evidence from this single dose
trial that PE-containing phospholipids can modulate
post-ingestive satiety and energy intake, even at relatively
high doses. Whether PE may play a role when adminis-
tered longer-term is not known.
Methods
Subjects
Eighteen healthy, non-smoking male adults were
recruited via advertisement. Participants had no self-
reported history of significant disease including cardio-
vascular disease, diabetes, or any other metabolic, endo-
crine or gastrointestinal disease. All were normotensive
and had normal clinical biochemistry as assessed by lipid
profile, full blood count and fasting blood glucose. None
of the participants were taking medications which may
have had an effect on appetite or weight regulation
throughout the trial. Written consent was obtained from
each participant and ethical approval obtained from the
Northern Regional Ethics Auckland, New Zealand.
Study design
This was a covert manipulation of dietary lipids which
varied in their content of the phospholipid, PE. All partic-
ipants in this randomised, cross-over were required to
attend the Human Nutrition Unit on 4 occasions, each for
a single day. Between treatment visits, participants
returned home for a minimum of 5 days washout with the
exception of 1 subject who completed his last visit with
only a 1 day washout between treatments. During the
washout period participants were requested not to make
significant changes to their usual diet and exercise pat-
terns wherever possible. Participants were also asked to
abstain from alcohol and strenuous physical activity for
24 hours prior to the study-day, and to fast from 2000 h
the previous evening. They completed a 24 h diet recall
and 24 h physical activity questionnaire for the day prior
to each treatment as a prompt to these requests. Partici-
pants were requested to arrive at the Unit using motorized
transport and avoid morning exercise. Upon arrival, body
weight and waist circumference were measured and any
adverse events or medications were recorded. They were
then given 200 ml water and completed the first series of
visual analogue scales (VAS) which rated their subjective
feelings of hunger, fullness, satisfaction and thoughts of
food [35]whilst fasted. The test-breakfast was served at
0830 h which was consumed in full within 15 minutes.
Participants remained within the Unit throughout each
treatment day and were allowed to read, write or under-
take other sedentary activities but were not allowed to
sleep.
Test-breakfast
On each study-day, participants received one of 4 test-
breakfasts in randomised order: (i) high-PE phospholi-
pid, (ii) medium-PE phospholipid, (iii) no-PE control
neutral lipid, (iv) water control. Each of the 3 lipid treat-
ments were matched for energy (2.5 MJ) and fat content
(53 en%). The 0 kJ water control was used to confirm that
the test system was sensitive to changes in energy. The test-
breakfasts comprised 2 savoury muffins plus 300 ml
water, or a 300 ml water control. The breakfasts were
designed using the dietary program FoodWorks™ (Profes-
sional Edition, Version 2.10.136, 1998–2000; Xyris Soft-
ware) and the macronutrient composition, PL and PE
content of the 4 breakfasts is shown in Table 2.
Dose of phospholipid and PE in the test-breakfasts
The high-PE treatment contained 2.42 g PL, of which
682.4 mg was PE which was equivalent to 9.75 mg/kg in
a 70 kg individual. The medium-PE treatment contained
1.96 g PL, of which 565.3 mg was PE which was equiva-
lent to 8.08 mg/kg in a 70 kg individual. Equivalent dose
levels in animal trials have been shown to decrease spon-
taneous EI in rats [17,18]
Visual analogue scales
VAS were used according to the standard methodology of
Flint and colleagues [35]. The following questions were
used: "How hungry do you feel?/How full do you feel?/
How satisfied do you feel?/How much do you think you
can eat now?" and were anchored on the left by "I am not
hungry/I am not full at all/I am completely empty/noth-
ing at all" and "I am as hungry as I have ever been/I am
totally full/I cannot eat another bite/a large amount" on
the right. A set of scales rating how thirsty, energetic and
relaxed the participants felt were included as a distraction
from the main outcome. Participants were asked to mark
their responses by placing a vertical line across the 100-
mm scale according to their subjective feelings. Identical
VAS questions presented on a separate page each time
were completed at baseline, 15, 30, 45, 60, 90, 120, 150,Lipids in Health and Disease 2008, 7:41 http://www.lipidworld.com/content/7/1/41
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180, 210, 270, 330, and 390 minutes after the subject
began eating the test-breakfast. Immediately after the test-
breakfast, participants also rated the pleasantness, visual
appeal, smell, taste, aftertaste and overall palatability of
the test-breakfast on separate 100-mm VAS.
Ad libitum lunch
The ad libitum lunch consisted of a restricted buffet-style
meal with predominantly cold and one hot meal choice,
along with a selection of beverages as shown in Table 4.
Prior to the study, it had been established with each sub-
ject that the items provided in the lunch were acceptable
as meal choices. In an attempt to avoid over-consumption
the variation of the items presented was limited. Each
meal item was served in excess and was covertly weighed
before and after the meal for calculation of energy and
macronutrient intake. Participants were served lunch at
1200 h, which was 3.5 hours after the test-breakfast, in
quiet, individual dining rooms and told that they could
eat as much or as little as they chose from the free selec-
tion over a 45 minute period. The study design, including
the long interval of 3.5 hours between the treatment and
lunch and the free choice buffet provided at the lunch,
was based on the trials of Livingstone and colleagues
where anorectic effects have been observed following
administration of lipid emulsions [9-11].
Statistical analysis
Energy, macronutrient intake and the weight of the food
consumed at the ad libitum lunch were analysed using the
dietary program FoodWorks™ (Professional Edition, Ver-
sion 2.10.136, 1998–2000; Xyris Software). Single factor
ANOVA (Microsoft Office Excel, 2003) was used to deter-
mine any differences in EI or physical activity level on the
day prior to each treatment visit. Single factor ANOVA
(Microsoft Office Excel, 2003) was also used to identify
any differences in body weight at baseline between the 4
treatments or any changes in body weight, BMI or waist
circumference throughout the trial. VAS data were ana-
lysed using repeated measures Linear Mixed Model
ANOVA (SAS: PROC MIXED, SAS version 8.0, SAS Insti-
tute Inc, Cary, NC, 2001). The subject, the dietary treat-
ment, the intervention period, and the study day were
included in the procedure, as was the treatment/time
interaction which addressed whether the trajectory over
time during the intervention period differed between
treatments (diet*time). Ad libitum lunch data was ana-
lysed using univariate ANOVA (SAS: PROC MIXED, SAS
version 8.0, SAS Institute Inc, Cary, NC, 2001). Statistical
significance was based on 95% limits (P < 0.05).
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Table 4: Energy and macronutrient composition of foods and beverages served at the ad libitum lunch
Food and beverage item Portion size (g) Energy (kJ) Protein (g) Fat (g) CHO (g)
Fried rice 924 4623 38.9 29.9 167.3
Bread, rye 168 1780 13.3 3.2 82.0
Bread, white 168 1814 13.6 3.2 83.8
Chicken breast, roasted 190 1170 48.1 9.8 0
Ham, smoked 190 868 30.4 3.8 13.3
Capsicum green, raw 68 45 0.6 0.3 1.5
Capsicum red, raw 68 99 1.2 0.1 4.6
Tomatoes, raw 127 86 1.1 0.3 3.4
Spiced apple & fruit loaf 400 5520 20.0 45.2 212.4
Apricot pieces tinned in fruit juice, drained 560 1125 3.4 0 45.9
Butter, spreadable 250 6458 2.5 175.0 3.5
Mayonnaise 250 3675 2.0 76.8 44.5
Soy sauce 300 297 3.0 0 15.0
Milk, full fat 1000 2550 31.0 33.0 47.0
Cola drink 1635 2943 0 0 178.2
Orange juice 1000 1820 6.0 2.0 100
Water, bottled 1500 0 0 0 0
Decaffeinated coffee and teas were also availableLipids in Health and Disease 2008, 7:41 http://www.lipidworld.com/content/7/1/41
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physician, clinical oversight of the participants, manu-
script preparation. AKM development and preparation of
the PE product. BHM biostatistician. SDP fundraiser, pro-
tocol design, study oversight, co-senior author.
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